WestGene Biopharma Co., Ltd., a biopharmaceutical company based in Chengdu, has announced that its drug candidate WGc-043 has been approved for clinical trials by the US Food and Drug Administration (FDA). WGc-043 is recognized as the world’s first clinically approved mRNA therapeutic vaccine targeting Epstein-Barr (EB) virus-related tumors. The vaccine is intended for the treatment of adult patients with EB virus-positive advanced solid tumors who have received at least second-line treatment, as well as adult patients with recurrent or refractory virus-positive hematomas.
WestGene has completed an investigator-initiated trial (ITT) for WGc-043 in nasopharyngeal carcinoma and natural killer T-cell lymphoma, showcasing superior safety and efficacy profiles compared to other mRNA tumor therapeutic vaccines currently available in the public domain.- Flcube.com
